Copyright Reports & Markets. All rights reserved.

Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Report 2018

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 Preface Market Performance (Volume)
      • 2.1.2 Eluxadoline Market Performance (Volume)
      • 2.1.3 Alosetron Market Performance (Volume)
      • 2.1.4 Rifaximin Market Performance (Volume)
      • 2.1.5 Loperamide Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.1.1 Preface Market Performance (Value)
      • 2.1.2 Eluxadoline Market Performance (Value)
      • 2.1.3 Alosetron Market Performance (Value)
      • 2.1.4 Rifaximin Market Performance (Value)
      • 2.1.5 Loperamide Market Performance (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Hospitals Market Performance (Volume)
      • 3.1.2 Clinics Market Performance (Volume)
      • 3.1.3 Others Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 Astellas Pharmaceuticals
      • 4.1.1 Astellas Pharmaceuticals Profiles
      • 4.1.2 Astellas Pharmaceuticals Product Information
      • 4.1.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
      • 4.1.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
    • 4.2 Actavis
      • 4.2.1 Actavis Profiles
      • 4.2.2 Actavis Product Information
      • 4.2.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
      • 4.2.4 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
    • 4.3 Pfizer
      • 4.3.1 Pfizer Profiles
      • 4.3.2 Pfizer Product Information
      • 4.3.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
      • 4.3.4 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
    • 4.4 GlaxoSmithKline
      • 4.4.1 GlaxoSmithKline Profiles
      • 4.4.2 GlaxoSmithKline Product Information
      • 4.4.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
      • 4.4.4 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
    • 4.5 Salix Pharmaceuticals Ltd
      • 4.5.1 Salix Pharmaceuticals Ltd Profiles
      • 4.5.2 Salix Pharmaceuticals Ltd Product Information
      • 4.5.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
      • 4.5.4 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
    • 4.6 AstraZenenca
      • 4.6.1 AstraZenenca Profiles
      • 4.6.2 AstraZenenca Product Information
      • 4.6.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
      • 4.6.4 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status

    5 Market Performance for Manufacturers

    • 5.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Market Share by Manufacturers 2013-2018
    • 5.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Market Share by Manufacturers 2013-2018
    • 5.3 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
    • 5.4 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 China Market Performance for Manufacturers
      • 6.1.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.1.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.1.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.1.4 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
      • 6.1.5 Market Concentration
    • 6.2 Japan Market Performance for Manufacturers
      • 6.2.1 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.2.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.2.3 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.2.4 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
      • 6.2.5 Market Concentration
    • 6.3 South Korea Market Performance for Manufacturers
      • 6.3.1 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.3.2 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.3.3 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.3.4 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
      • 6.3.5 Market Concentration
    • 6.4 Taiwan Market Performance for Manufacturers
      • 6.4.1 Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.4.2 Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.4.3 Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.4.4 Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
      • 6.4.5 Market Concentration
    • 6.5 India Market Performance for Manufacturers
      • 6.5.1 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.5.2 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.5.3 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.5.4 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
      • 6.5.5 Market Concentration
    • 6.6 Southeast Asia Market Performance for Manufacturers
      • 6.6.1 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.6.2 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.6.3 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.6.4 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
      • 6.6.5 Market Concentration
    • 6.7 Australia Market Performance for Manufacturers
      • 6.7.1 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.7.2 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.7.3 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.7.4 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
      • 6.7.5 Market Concentration
    • 6.8 Market Performance for Manufacturers
      • 6.8.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.8.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.8.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.8.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
      • 6.8.5 Market Concentration

    7 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Performance (Sales Point)

    • 7.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Market Share by Regions 2013-2018
    • 7.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Market Share by Regions 2013-2018
    • 7.3 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Regions 2013-2018
    • 7.4 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin by Regions 2013-2018

    8 Development Trend for Regions (Sales Point)

    • 8.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.3 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.4 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.5 Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.6 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.7 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Hospitals Industry
    • 11.2 Clinics Industry
    • 11.3 Others Industry

    12 Market Forecast 2019-2024

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
      • 12.1.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
      • 12.1.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Growth Rate 2019-2024
      • 12.1.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.4 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.5 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.6 Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.7 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.8 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.9 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.10 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
      • 12.3.1 Overall Market Performance
      • 12.3.2 Preface Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.3 Eluxadoline Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.4 Alosetron Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.5 Rifaximin Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.4 Sales by Application 2019-2024
      • 12.4.1 Overall Market Performance
      • 12.4.2 Hospitals Sales and and Growth Rate 2019-2024
      • 12.4.3 Clinics Sales and and Growth Rate 2019-2024
      • 12.4.4 Others Sales and and Growth Rate 2019-2024
    • 12.5 Price (USD/Unit) and Gross Profit
      • 12.5.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) Trend 2019-2024
      • 12.5.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Profit Trend 2019-2024

    13 Conclusion

    Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs for these regions, from 2012 to 2023 (forecast), including
    China
    Japan
    South Korea
    Taiwan
    India
    Southeast Asia
    Australia

    Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market competition by top manufacturers/players, with Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Astellas Pharmaceuticals
    Actavis
    Pfizer
    GlaxoSmithKline
    Salix Pharmaceuticals Ltd
    AstraZenenca
    ...

    On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Preface
    Eluxadoline
    Alosetron
    Rifaximin
    Loperamide
    Diphenoxylate + Atropine
    ? ? Dicyclomine and Hyoscyamine

    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs for each application, including
    Hospitals
    Clinics
    Others

    If you have any special requirements, please let us know and we will offer you the report as you want.

    Buy now